|Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.||CEO, COO & Member of Management Board||729.76k||N/A||1970|
|Dr. Florian von der Mulbe M.B.A., Ph.D., MBA||Co-Founder, Member of Management Board & Chief Production Officer||629.74k||N/A||1973|
|Mr. Pierre Kemula B.Sc.||CFO & Member of Management Board||709.9k||N/A||1974|
|Ms. Mariola Fotin-Mleczek||CTO & Member of Management Board||567.71k||N/A||1968|
|Ms. Ulrike Gnad-Vogt Ph.D., M.D.||Interim Chief Devel. Officer & Member of Exec. Board||429.49k||N/A||1972|
|Dr. Igor Splawski M.Sc., Ph.D.||Chief Scientific Officer & Member of Management Board||478.5k||N/A||1969|
|Dr. Ingmar Hoerr||Co-Founder, CEO & Supervisory Board Chairman (Leave of Absence)||25.83k||N/A||N/A|
|Dr. Antony Blanc||Chief Bus. Officer & Chief Commercial Officer||432.76k||N/A||1969|
|Dr. Sarah Fakih||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Thorsten Schuller||Head of Corp. Communications||N/A||N/A||N/A|
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in TÃ¼bingen, Germany.
CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.